openPR Logo
Press release

Sanfilippo Syndrome Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

05-21-2025 01:36 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Sanfilippo Syndrome Pipeline Appears Robust With 8+ Key Pharma

DelveInsight's, "Sanfilippo Syndrome Pipeline Insight 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Sanfilippo Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sanfilippo Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Sanfilippo Syndrome Pipeline. Dive into DelveInsight's comprehensive report today! @ Sanfilippo Syndrome Pipeline Outlook [https://www.delveinsight.com/sample-request/sanfilippo-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Sanfilippo Syndrome Pipeline Report

* In May 2025, JCR Pharmaceuticals Co., Ltd . announced a Phase I/ II study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIA patients.
* In May 2025, Denali Therapeutics Inc . announced a phase 1/2 study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of DNL126 in participants with Sanfilippo syndrome Type A (MPS IIIA). The core study period is 25 weeks (approximately 6 months) and is followed by a 72-week (approximately 18 month) open-label extension (OLE). Participants with MPS IIIA will be enrolled in two planned cohorts, and additional participants with MPS IIIA may be enrolled in three optional cohorts.
* DelveInsight's Sanfilippo Syndrome Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Sanfilippo Syndrome treatment.
* The leading Sanfilippo Syndrome Companies such as Ultragenyx Pharmaceutical Inc, JCR Pharmaceuticals Co., Ltd., GC Biopharma Corp, Denali Therapeutics Inc., Orchard Therapeutics plc, Seelos Therapeutics and others.
* Promising Sanfilippo Syndrome Pipeline Therapies such as JR-446, anakinra, SAF-301, UX111, SOBI003, DNL126, SBC-103, AX 250 and others.

Stay ahead with the most recent pipeline outlook for Sanfilippo Syndrome. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Sanfilippo Syndrome Treatment Drugs [https://www.delveinsight.com/sample-request/sanfilippo-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Sanfilippo Syndrome Emerging Drugs Profile

* UX111: Ultragenyx Pharmaceutical Inc.

UX111 (rebisufligene etisparvovec) is an investigational novel in vivo gene therapy under evaluation for Sanfilippo syndrome type A (MPS IIIA). UX111 is designed to be dosed in a one-time intravenous infusion using a self-complementary AAV9 vector to deliver a functional copy of the SGSH gene to cells. The therapy is designed to address the underlying sulfamidase enzyme deficiency responsible for abnormal accumulation of heparan sulfate, a glycosaminoglycan, in the brain that results in progressive cell damage and neurodegeneration. The UX111 program has received Regenerative Medicine Advanced Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations in the U.S., and PRIME and Orphan Drug designations in the EU. In December 2024, Ultragenyx Pharmaceutical announced the submission of a Biologics License Application to the US Food and Drug Administration seeking accelerated approval for UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A.

* OTL-201: Orchard Therapeutics

OTL-201 is an ex vivo autologous gene therapy being developed for the treatment of Sanfilippo syndrome. It uses a modified virus to insert a functional copy of the SGSH gene into a patient's cells. OTL-201 has received rare pediatric disease designation from the FDA and is currently being evaluated in an ongoing proof-of-concept clinical trial. OTL-201 is an investigational therapy and has not been approved by any regulatory agency or health authority.

* DNL126: Denali Therapeutics Inc.

DNL126 is an investigational enzyme replacement therapy developed for the treatment of Sanfilippo Syndrome type A (MPS IIIA). Utilizing Denali's proprietary Enzyme Transport Vehicle (ETV) technology, DNL126 is designed to effectively cross the blood-brain barrier through receptor-mediated transcytosis, allowing for targeted delivery of SGSH to the central nervous system. By replenishing the deficient enzyme, DNL126 aims to reduce the toxic buildup of heparan sulfate in brain tissues, potentially alleviating neurological symptoms and improving overall outcomes for patients. DNL126 is a recombinant SGSH enzyme engineered to cross the blood-brain barrier, replace the SGSH enzyme and treat neuropathic and systemic forms of the Sanfilippo syndrome A. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Sanfilippo Syndrome.

The Sanfilippo Syndrome Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Sanfilippo Syndrome with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sanfilippo Syndrome Treatment.
* Sanfilippo Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Sanfilippo Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sanfilippo Syndrome market

Explore groundbreaking therapies and clinical trials in the Sanfilippo Syndrome Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Sanfilippo Syndrome Drugs [https://www.delveinsight.com/sample-request/sanfilippo-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Sanfilippo Syndrome Companies

Ultragenyx Pharmaceutical Inc, JCR Pharmaceuticals Co., Ltd., GC Biopharma Corp, Denali Therapeutics Inc., Orchard Therapeutics plc, Seelos Therapeutics and others.

Sanfilippo Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Sanfilippo Syndrome Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Unveil the future of Sanfilippo Syndrome Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Sanfilippo Syndrome Market Drivers and Barriers [https://www.delveinsight.com/sample-request/sanfilippo-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Sanfilippo Syndrome Pipeline Report

* Coverage- Global
* Sanfilippo Syndrome Companies- Ultragenyx Pharmaceutical Inc., JCR Pharmaceuticals Co., Ltd., GC Biopharma Corp, Denali Therapeutics Inc., Orchard Therapeutics plc, Seelos Therapeutics and others.
* Sanfilippo Syndrome Pipeline Therapies- JR-446, anakinra, SAF-301, UX111, SOBI003, DNL126, SBC-103, AX 250 and others.
* Sanfilippo Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Sanfilippo Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Sanfilippo Syndrome Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Sanfilippo Syndrome Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/sanfilippo-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Sanfilippo Syndrome: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Sanfilippo Syndrome- DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* UX111: Ultragenyx Pharmaceutical Inc
* Drug profiles in the detailed report.....
* Mid-Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* DNL126: Denali Therapeutics Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Sanfilippo Syndrome Key Companies
* Sanfilippo Syndrome Key Products
* Sanfilippo Syndrome- Unmet Needs
* Sanfilippo Syndrome- Market Drivers and Barriers
* Sanfilippo Syndrome- Future Perspectives and Conclusion
* Sanfilippo Syndrome Analyst Views
* Sanfilippo Syndrome Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sanfilippo-syndrome-pipeline-appears-robust-with-8-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sanfilippo-syndrome-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sanfilippo Syndrome Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here

News-ID: 4027004 • Views:

More Releases from ABNewswire

The Debut Album of Soldier'z of the Most High (S.O.T.M.H): The City in the Sky Now Available on All Major Platforms - SalvationMusic.com
The Debut Album of Soldier'z of the Most High (S.O.T.M.H): The City in the Sky N …
From sourthern roots and legendary encounters to a new sound called Salvation Music, Chattanooga's own Freddy Mac delivers his long-awaited debut album. Chattanooga, TN - The wait is over. Freddy Mac 2025 and his band Soldier'z of the Most High (S.O.T.M.H) proudly unveil their long-anticipated debut album, The City in the Sky. This groundbreaking project introduces Salvation Music [http://www.salvationmusic.com], a bold fusion of funk, metal, soul, and classical influences, brought to
Author's Tranquility Press Announces the Heartwarming Release of Lil' Hal's Giant Christmas Box
Author's Tranquility Press Announces the Heartwarming Release of Lil' Hal's Gian …
A Christmas Tale of Wonder, Patience, and Family Love That Shines Beyond the Wrapping Paper Few things capture the spirit of Christmas like the thrill of a child discovering a gift under the tree. In Lil' Hal's Giant Christmas Box [https://www.amazon.com/Lil-Hals-Giant-Christmas-Box/dp/195754662X/ref=monarch_sidesheet_title] by Christy B., readers are invited into a magical holiday morning filled with suspense, laughter, and an unforgettable lesson: sometimes the greatest gifts require patience, faith, and love. This beautifully illustrated
"The Expedia of VoIP": Business Phone System Disrupts Carrier Model with Transpa …
Business owners can now shop multiple providers at once-choosing the right system without sales pressure or hidden fees. Sheridan, Wyoming - Business Phone System, a vendor-neutral platform for business communications, today announced its official launch, offering business owners a smarter way to evaluate and select telecom services. Unlike traditional carriers that push their own packages, Business Phone System enables organizations to compare multiple providers side-by-side, ensuring the right solution is sized
Skerrit Bwoy Launches Explosive New Single
Skerrit Bwoy Launches Explosive New Single "Satan Dead" - A Bold Christian EDM A …
Album Release: August 29, 2025 New York, NY - Antiguan-born, Bronx-raised producer and DJ Skerrit Bwoy, widely recognized as "Mr. Jesus Party", is set to shake the Christian music scene with the release of his latest single, "Satan Dead." Available today on all major streaming platforms, the track delivers a powerful fusion of festival-ready EDM drops, Caribbean dancehall vibes, and unapologetically Gospel-driven lyrics. More than just a song, "Satan Dead" is a

All 5 Releases


More Releases for Sanfilippo

Sanfilippo Syndrome Market Forecast: Growth Trends, Key Players & Future Outlook …
The most recent in-depth analysis from CoherentMI offers a comprehensive global perspective on the evolving Sanfilippo Syndrome Market, equipping industry stakeholders with data-backed insights into shifting market dynamics, innovation cycles, and emerging business models. This report serves as a trusted roadmap for organizations navigating a landscape shaped by increasing competition, technological disruption, and fluctuating demand across geographies. From strategic positioning to investment trends, the study provides clarity on both micro
Sanfilippo Syndrome Market Future Business Opportunities 2025-2032 | Amgen Inc, …
The Global Sanfilippo Syndrome Market is estimated to be valued at USD 10.62 Bn in 2025 and is expected to reach USD 20.05 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032. The Latest published market study on Sanfilippo Syndrome Market report provides an overview of the current market dynamics as well as what our survey respondents- all outsourcing decision-makers- predict the market
Sanfilippo Syndrome Market Forecasted for Strong Growth from 2025 to 2032 | Amge …
The Global Sanfilippo Syndrome Market is estimated to be valued at USD 9.7 Bn in 2024 and is expected to reach USD 19.8 Bn by 2031, growing at a compound annual growth rate (CAGR) of 9.3% from 2024 to 2031. According to the latest research from CoherentMI, the Sanfilippo Syndrome Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on
Sanfilippo Syndrome Market is Projected to Grow at a CAGR of 3.68% from 2023-203 …
Market Overview: The sanfilippo syndrome market is expected to exhibit a CAGR of 3.68% during 2023-2033. The report offers a comprehensive analysis of the sanfilippo syndrome market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions.
China Sanfilippo Syndrome (MPS-III) Therapeutics Market Report with Executive Su …
Report Overview China Sanfilippo Syndrome (MPS-III) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period. Sanfilippo syndromeis a rare genetic metabolismdisorder. A change in a single gene makes a child's body unable to break down certain carbohydrates (sugars). This leads to serious problems in the brain and nervous system. MPS III
Recipe Pecan market: Promising Regions for Companies in 2022 | John B. Sanfilipp …
" The global Recipe Pecan Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Recipe Pecan Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global